The TSO 500 HRD research test aligns Myriad's gold standard MyChoice® CDx HRD technology with Illumina's pan-cancer test, TSO 500. The test was codeveloped with Merck (known as MSD outside the US and ...

SALT LAKE CITY, June 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN) (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with GSK aimed at ...

A community-based study found that despite current guidelines recommending that all patients diagnosed with epithelial ovarian cancer undergo testing for homologous repair deficiency (HRD), only about ...

SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced updates to its agreement with Illumina Inc.

Starting in 2014, poly (ADP-ribose) polymerase inhibitors (PARPi) have been approved for the treatment of BRCA-mutated (BRCAm) and/or homologous recombination deficiency (HRD)-positive ovarian cancer, ...

Myriad Genetics, Inc. (NASDAQ: MYGN) today announced new clinical studies on its myChoice HRD companion diagnostic test at the 2015 American Society of Clinical Oncology annual meeting being held in ...

Targeting ALKBH5 with cisplatin-Ga nanodrug to investigate platinum sensitivity in resistant ovarian cancer through m6A-dependent mechanisms. Intermittent PARP inhibitor regimen in ovarian cancer ...